You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The firm launched a study this year to validate the new CRC-specific immune-transcriptomic assay, aiming to obtain regulatory approval in Europe.
Qiagen's test is intended to identify advanced bladder cancer patients with alterations in FGFR3 or FGFR2 genes and who are likely to respond to erdafitinib.
The firm's new RT-PCR assay identifies 20 gene fusion between NTRK1/2/3 and other genes, allowing clinicians to potentially detect rare forms of different cancers.
Qiagen and Foundation Medicine will develop tissue- and plasma-based companion tests to identify best responders to the PI3K inhibitor alpelisib